curasan AG Receives Approval for Cerasorb® M ORTHO in Canada
curasan AG has received the certification for the synthetic bone regeneration material Cerasorb® M ORTHO from the Canadian authorities, Health Canada.
Kleinostheim, Germany, November 20, 2010 --(PR.com)-- curasan AG, listed in the General Standard (ISIN: DE 000 549 453 8) has received the certification for the synthetic bone regeneration material Cerasorb® M ORTHO from the Canadian authorities, Health Canada.
“This news has come as a pleasant surprise,” stated Hans Dieter Rössler, CEO. “Since the approval process for medical devices by the Canadian authorities is highly demanding, we were actually expecting the certification some time next year.”
Cerasorb® M ORTHO is now approved for sales in the whole of North America. Furthermore, curasan AG considers that the experience gained with the authorities in Canada will be useful and beneficial for other product approvals in this market. This is a significant development for potential sales partners since further new bio materials are expected to be available earlier for market launch.
Background information about curasan AG:
Exchange listed curasan AG (ISIN: DE 000 549 453 8) is one of the leading firms in the field of regenerative medicine especially in bone and tissue regeneration. In addition to the synthetic Cerasorb® bone substitution and regeneration material, the company has developed a future-oriented product pipeline. The goal during the next few years is to have further medical products ready for market rollout via well-positioned contractual partners in various market segments.
###
“This news has come as a pleasant surprise,” stated Hans Dieter Rössler, CEO. “Since the approval process for medical devices by the Canadian authorities is highly demanding, we were actually expecting the certification some time next year.”
Cerasorb® M ORTHO is now approved for sales in the whole of North America. Furthermore, curasan AG considers that the experience gained with the authorities in Canada will be useful and beneficial for other product approvals in this market. This is a significant development for potential sales partners since further new bio materials are expected to be available earlier for market launch.
Background information about curasan AG:
Exchange listed curasan AG (ISIN: DE 000 549 453 8) is one of the leading firms in the field of regenerative medicine especially in bone and tissue regeneration. In addition to the synthetic Cerasorb® bone substitution and regeneration material, the company has developed a future-oriented product pipeline. The goal during the next few years is to have further medical products ready for market rollout via well-positioned contractual partners in various market segments.
###
Contact
curasan AG
Andrea Weidner
+49 (0)6027 40 900-51
www.curasan.de
Andrea Weidner
+49 (0)6027 40 900-51
www.curasan.de
Contact
Categories